Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cuneo, A.
Right arrow Articles by Castoldi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cuneo, A.
Right arrow Articles by Castoldi, G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 18, Issue 13 (July), 2000: 2607-2614
© 2000 American Society for Clinical Oncology

Acquired Chromosome 11q Deletion Involving the Ataxia Teleangiectasia Locus in B-Cell Non-Hodgkin’s Lymphoma: Correlation With Clinicobiologic Features

By Antonio Cuneo, Renato Bigoni, Gian Matteo Rigolin, Maria Grazia Roberti, Raffaella Milani, Antonella Bardi, Claudia Minotto, Paola Agostini, Cristiano De Angeli, Maria Grazia Narducci, Silvia Sabbioni, Giandomenico Russo, Massimo Negrini, Gianluigi Castoldi

From the Dipartimento di Scienze Biomediche e Terapie Avanzate, Sezione di Ematologia, and Dipartimento di Medicina Sperimentale e Diagnostica, Sezione di Microbiologia, University of Ferrara, Ferrara, and Istituto Dermopatico dell’Immacolata, IRCCS, Roma, Italy.

Address reprint requests to Antonio Cuneo, MD, Dipartimento di Scienze Biomediche, Sezione di Ematologia Università di Ferrara, Via Savonarola, 9 - 44100 Ferrara, Italy; email sse{at}dns.unife.it

PURPOSE: To study the clinicobiologic significance of acquired 11q deletions involving the ataxia teleangiectasia locus (ATM+/-) in B-cell non-Hodgkin’s lymphomas (NHL).

PATIENTS AND METHODS: Fifty-three indolent lymphomas and 82 aggressive lymphomas were studied by conventional cytogenetic analysis and by fluorescence in situ hybridization using an 11q22–23 probe recognizing ATM sequences. Pertinent clinical data were collected.

RESULTS: A hemizygous ATM deletion was seen in 44% to 88% of the interphase cells in 15 cases (11.1%); four patients had an indolent lymphoma (follicular center cell lymphoma), and 11 patients had an aggressive lymphoma (five mantle-cell lymphomas [MCLs] and six diffuse large-cell lymphomas). Dual-color hybridization studies showed ATM deletion to be possibly a secondary aberration in three patients with MCL. Ten out of 15 ATM+/- patients had a complex karyotype, 11 out of 15 had more than 90% abnormal metaphases (AA karyotype status), and +12, 13q14 deletion, and 17p13 deletion were seen in seven, four, and five cases, respectively. Patients with ATM+/- more frequently had a complex karyotype (P = .01) and the AA karyotype (P = .04) compared with patients without ATM+/-. With the exception of a poor performance status (P = .001), no correlation was found between ATM+/-, initial clinical variables, and complete remission rate; whereas a highly significant association was found with shorter survival (P < .0001). This cytogenetic lesion maintained its prognostic importance in multivariate analysis (P = .0004), along with performance status (P = .0006), serum lactate dehydrogenase level (P = .03), splenomegaly (P = .01), and histologic grade (P = .03). When analyzing indolent lymphomas and aggressive lymphomas separately, ATM+/- maintained its prognostic importance as an independent variable in both histologic groups (P = .0001 and P = .016, respectively).

CONCLUSION: Though possibly not representing a primary genetic lesion in the majority of cases, the acquired ATM+/- status has clinicobiologic importance in NHL, possibly representing a major cytogenetic determinant of outcome.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
BloodHome page
M. Reimann, C. Loddenkemper, C. Rudolph, I. Schildhauer, B. Teichmann, H. Stein, B. Schlegelberger, B. Dorken, and C. A. Schmitt
The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo
Blood, October 15, 2007; 110(8): 2996 - 3004.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
K. Fukino, L. Shen, A. Patocs, G. L. Mutter, and C. Eng
Genomic Instability Within Tumor Stroma and Clinicopathological Characteristics of Sporadic Primary Invasive Breast Carcinoma
JAMA, May 16, 2007; 297(19): 2103 - 2111.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Molica, A. Vacca, D. Ribatti, A. Cuneo, F. Cavazzini, D. Levato, G. Vitelli, L. Tucci, A. M. Roccaro, and F. Dammacco
Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia
Blood, October 16, 2002; 100(9): 3344 - 3351.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Gronbak, J. Worm, E. Ralfkiaer, V. Ahrenkiel, P. Hokland, and P. Guldberg
ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma
Blood, July 30, 2002; 100(4): 1430 - 1437.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
J Boultwood
Ataxia telangiectasia gene mutations in leukaemia and lymphoma
J. Clin. Pathol., July 1, 2001; 54(7): 512 - 516.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2000 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online